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Abstract: Human cytomegalovirus (HCMV) infects more than 70% of the human population
worldwide. HCMV is responsible for high morbidity and mortality in immunocompromised patients
and remains the leading viral cause of congenital birth defects. Despite considerable efforts in
vaccine and therapeutic development, HCMV infection still represents an unmet clinical need and
a life-threatening disease in immunocompromised individuals and newborns. Immune repertoire
interrogation of HCMV seropositive patients allowed the identification of several potential antigens
for vaccine design. However, recent HCMV vaccine clinical trials did not lead to a satisfactory
outcome in term of efficacy. Therefore, combining antigens with orthogonal technologies to further
increase the induction of neutralizing antibodies could improve the likelihood of a vaccine to reach
protective efficacy in humans. Indeed, presentation of multiple copies of an antigen in a repetitive
array is known to drive a more robust humoral immune response than its soluble counterpart.
Virus-like particles (VLPs) and nanoparticles (NPs) are powerful platforms for multivalent antigen
presentation. Several self-assembling proteins have been successfully used as scaffolds to present
complex glycoprotein antigens on their surface. In this review, we describe some key aspects of the
immune response to HCMV and discuss the scaffolds that were successfully used to increase vaccine
efficacy against viruses with unmet medical need.
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1. Introduction
Human cytomegalovirus (HCMV) is a ubiquitously distributed member of the Herpesviridae
family belonging to the Betaherpesvirinae sub-family; it infects 70% of the human adult population
worldwide [1,2] and primary infection is usually asymptomatic in immunocompetent individuals.
Nevertheless, the virus establishes a lifelong latency of the host after a primary infection and viral
reactivation is common, also it does not necessarily imply clinical symptoms [1,3]. However, infection
or viral reactivation in immunodeficient individuals such as AIDS patients, solid organ (SOT) or
hematopoietic stem cells (HSCT) transplant patients causes morbidity and mortality [4,5]. Furthermore,
HCMV is the most common viral cause of congenital birth defects affecting 0.7% of the newborns with
permanent sequelae such as sensorineural hearing loss, growth restriction, and cognitive disabilities [6].
Current antiviral therapies and transfusion with hyper-immune globulins to control viremia are not
efficient [7]. Therefore, given the severity and importance of these diseases, as well as the associated
socioeconomic cost, the need for an HCMV vaccine has been assigned in the highest priority category
by the Institute of Medicine and it represents the second highest priority target after HIV by the Centers
for Disease Control [8,9]. Over the last decades, considerable efforts were deployed to develop a
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vaccine capable of preventing HCMV infection, congenital transmission and viral spreading after SOT
or HSCT from seropositive donors to seronegative recipients [10]. The potential vaccine included
live virus, attenuated or vectored viral vaccines expressing HCMV immunogens as well as purified
recombinant protein vaccines that have been evaluated in clinical trials [11,12]. The abundant virion
envelope glycoprotein B (gB) was shown to elicit vigorous T cell and antibody responses and represents
the basis of most vaccines developed so far [13]. In a recent phase II clinical trial the recombinant
gB vaccine formulated in MF59 adjuvant (gB/MF59), an oil-in-water emulsion, generated antibody
titers comparable to natural infection. However, the vaccine demonstrated only modest efficacy in
preventing primary HCMV infections in seronegative women and in the reduction of viremia in
transplant recipients [14,15]. Surprisingly, a recent study demonstrated that seronegative patients
vaccinated with the gB/MF59 vaccine developed a faster humoral response against gB after solid
organ transplantation from seropositive donors [16]. Still, it is of the utmost importance to evaluate
possible strategies for HCMV next generation vaccines. In this review, we will summarize the current
findings on the adaptive immune response to HCMV and provide an update on the new methodologies
available to boost the immune response against infectious diseases using virus-like particles (VLPs)
and nanoparticles (NPs).
2. Immune Response against HCMV
The establishment of a long-lasting immunity in response to a primary HCMV infection is required
to control subsequent HCMV reactivation and prevent uncontrolled viral replication or serious
HCMV diseases [17,18]. HCMV infection activates both humoral and cellular immune responses.
It is commonly believed that cellular immunity controls most of HCMV replication. Nonetheless,
HCMV-specific antibodies have been associated with the prevention and protection from reinfection
as well as the congenital transmission of HCMV [6,19,20]. Despite this, it is clear that the humoral
response on its own is not able to clear the virus and prevent viral reactivation [21,22]. Nevertheless,
the two arms of the adaptive immune response appear to be necessary for protection and resolution of
HCMV infection [23].
2.1. Cellular Immune Response against HCMV
The primary cellular response to HCMV infection arises from natural killer (NK) cells, which
trigger the release of inflammatory cytokines and cause lysis or apoptosis of infected cells [24].
Secondly, T cells restrict HCMV viral replication and viral spreading, although they are not able to
definitively clear the virus [25–27]. HCMV-specific T cells represent 10% of both the CD4+ and CD8+
memory compartments in the peripheral blood of CMV-seropositive individuals [28]. CD8+ T cells
release perforin and granzyme B to promote lysis of infected cells that present CMV peptides on
MHC-I [29,30], while CD4+ specific T cells present a typical Th1 cytokine secretion signature (IFN-γ and
TNF-α) [31]. Immune repertoire interrogation using 13,687 spanning peptides to cover 213 predicted
CMV-proteins [32] revealed that human T cells recognize at least 151 HCMV proteins. Among these,
CD4+ T cells recognize 125 proteins, while CD8+ T cells recognize 107 proteins, and 81 proteins are
recognized by both cell types. Although the HCMV-specific T cell response is very broad, the vast
majority of the results points toward antigens that are highly conserved among different HCMV
strains, such as the 65 kDa phosphoprotein (pp65) and the immediate early 1 (IE1) proteins, which are
recognized by more than 50% of seropositive individuals [28]. CD8+ T cells were proven to have a
protective role in both HSCT and SOT recipients [33–35] and a function in preventing congenital HCMV
infection [36]. However, one of the paradoxes of the cellular immunity against HCMV comes from the
observation that HCMV does induce a very large T cell response, meanwhile the virus also possesses
sophisticated and numerous immune evasion mechanisms [37]. Among those, the capacity of the virus
to enter a latency state has been the subject of intense investigation. Indeed, while primary infection
of immunocompetent individuals by HCMV is rarely the source of disease, the opposite is true for
individuals with an immune system that is still immature (fetus) or compromised (HIV/AIDS and
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transplantations). Consequently, several studies sought to identify the antigens that are relevant for the
latency phase. A vaccine able to boost the immune system against the latter would help clearing the
latent reservoir of the virus. It is known that HCMV establishes latency in the myeloid cell lineage and
viral genome has been detected in peripheral blood monocytes and in CD34+ progenitors in the bone
marrow [38–40]. The viral gene expression program in these cells is restricted and extremely different
from the one established during lytic infections. HCMV latent transcriptome is an area of extensive
research, and at present, the exact roles of many latency-associated genes remain unclear. Nevertheless,
several studies identified a number of viral genes that are specifically associated with latency [41,42].
Notably, RNAs from the major IE region (UL122–123 CLTs) [43], Latency Unique Natural Antigen
(LUNA) [44], UL138 [41], UL111a (encoding a viral IL-10 homologue (LAcmvIL-10)) [45], UL144 [46]
and US28 [47] were identified [22]. Moreover, viral reactivation is also associated with the expression
of the major immediate early proteins (IE72 and IE86) [48]. T-cell repertoire interrogation identified
four viral proteins expressed during latency (LUNA, UL138, US28, and LAcmvIL-10). Interestingly,
these proteins can be recognized by CD4+ T cells and T-cell responses specific for all four proteins
are detectable in healthy HCMV-positive donors [49]. Accordingly, future vaccine candidates should
boost cellular immunity against some of these proteins representing key targets for viral clearance.
2.2. Humoral Immune Response against HCMV
Upon HCMV infection, a large quantity of the antibodies generated target the most abundant
viral proteins. These include proteins from the tegument (i.e., pp65), the immediate early proteins (i.e.,
IE1), and envelope glycoproteins such as gB, gM/gN, and the gH/gL complexes (trimer and pentamer).
Antibodies targeting antigens that are not exposed on the surface of the virion are unlikely to generate an
efficient protection against the virus [10]. Nonetheless, antibodies targeting the envelope glycoproteins
are able to neutralize viral infection in vitro and correlate with a decrease of viral transmission in
primary infected pregnant women [50]. It is known that antibodies targeting the pentamer are the most
potent neutralizers at least in vitro [51,52], while antibodies targeting gHgL and gB are a thousand
times less potent [51]. This result is still not fully understood, since the gHgL and gB proteins form
the core machinery for viral membrane fusion [53] and monoclonal antibodies (mAbs) targeting the
fusion machinery of other herpesviruses, such as Epstein–Barr virus, are potent neutralizers [54].
Immune repertoire interrogation of HCMV seropositive donors allowed the identification of multiple
mAbs targeting the pULs subunits. We recently demonstrated that these mAbs neutralize the virus
by blocking the molecular recognition of the pentamer to its cellular host receptor Neuropilin 2 [55].
In contrast, mAbs targeting gH are supposed to prevent the activation of the fusion machinery [56].
These mAbs were assigned to only two antigenic regions of gH, indeed 3G16 and MSL-109 mAbs bind
toward the C-terminus of gH, while the 13H11 mAb binds close to the gL interaction site [57].
Recently, two studies reported the results of the recombinant gB vaccine formulated in MF59
adjuvant, which demonstrated partial efficacy in reducing viraemia after SOT and preventing primary
infection in women and adolescents [14,15]. Sera analysis from gB-vaccinated individuals allowed the
characterization of at least five gB antigenic domains (AD-1 to AD-5). The AD-1 is a domain of 80 amino
acids between amino acid 560 and 640 whereas AD-2 consists of two discontinuous binding sites: Site I,
located between amino acids 68 and 77, is highly conserved among strains and is considered as a target
of neutralizing responses, while Site II, located between amino acids 50 and 54, is less conserved. AD-3
is a linear epitope corresponding to amino acids 798–805 in the intraluminal region of gB. AD-4, like
AD-2, is a discontinuous domain corresponding to amino acids 121–132 and 344–438. AD-5 matches to
amino acids between 133 and 343 [58–60]. Interestingly, Baraniak et. al. demonstrated that vaccination
only boosted AD-2 responses in the 50% of CMV+ individuals with a preexisting response and did not
induce a new AD-2 response in those who lacked AD-2 antibodies following natural infection [15,61].
In parallel, Nelson et al. observed an increase of anti-gB IgG titer induced by the same vaccine in
a cohort of CMV-post-partum women [14]. However, the authors also subsequently observed that
76% of the vaccine-induced IgG response recognized AD-3. Considering that AD-3 is located in the
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intraluminal part of the virus, antibodies against this region will be most probably non-protective [12].
The hypothesis that AD-3 is diverting the immune response away from antigenic sites that more likely
induce protective antibody responses (AD-2), was recently proposed [62]. The next HCMV vaccines
will have to contain multiple antigens that should induce a strong neutralizing antibody response
protecting from primary infections and an efficient T-cell response to prevent viral reactivation and to
clear the latent virus.
3. HCMV Antigens as Vaccine Candidates
HCMV is the largest virus infecting humans, with a genome containing a linear double-stranded
DNA of about 230 kb, from which at least 170 open reading frames (ORFs) have been identified [63,64].
The virus contains over 30 structural proteins and encodes at least 20 membrane glycoproteins expressed
on the virion envelope, which are involved in immune evasion, cell attachment, and viral entry. HCMV
exhibits an extremely broad cellular tropism being able to infect different cell types ranging from
epithelial, endothelial, fibroblasts, myeloid hematopoietic precursors, monocytes/macrophages to
smooth muscle cells, stromal cells, neurons, astrocytes, hepatocytes and glial cells [65]. Identification
of the host cellular receptors has been a subject of debate during the last decade. It is now accepted
that the two main host cell receptors for HCMV involve the platelet-derived growth factor receptor
α (PDGFRα) [66–68] and Neuropilin 2 (Nrp2) [55]. In addition, other cellular host factors were
described as facilitators of viral entry such as the olfactory receptor family member OR14I1 [69], the
adipocyte plasma membrane-associated protein (APMAP) [70], CD46 [71], and CD147 [72]. However,
the biological relevance of this multitude of receptors remains to be understood. In contrast, the
viral ligands responsible for the broad cellular tropism were clearly identified and correspond to two
viral envelope complexes: the gHgLgO (trimer) and the gHgLpUL128pUL130pUL131A (pentamer)
(Figure 1) [73]. The trimer is a heterocomplex, in which the heterodimer consisting of gH (UL75) and
gL (UL115) is disulfide-linked to glycoprotein O (gO), a heavily N-glycosylated polypeptide encoded
by UL74 [74–76]. The trimer complex binds PDGFRα and is required for entry in all cell types [77],
representing an attractive target for vaccine design. However, the gO sequence heterogeneity and the
large glycan shield present on this subunit are impairing the generation of potent neutralizing mAbs.
Along with others, we speculate that these issues will probably slow down possible efforts to use the
trimer as a vaccine candidate [78]. The pentamer complex is composed of the gHgL heterodimer bound
to three additional glycoproteins encoded by pUL128, pUL130, and pUL131A. The pentamer complex
is required for viral entry in epithelial, endothelial, and myeloid cells and binds Nrp2 [55,65,79].
It represents the main target of HCMV neutralizing antibodies, eliciting a protective response targeting
the pULs subunits, which is several orders of magnitude more potent than any other response against
HCMV glycoprotein [51,52,80]. However, anti-pULs mAbs are not able to block infection in all cell
types, in contrast to mAbs directed against gH and gB subunits [81]. Indeed, membrane fusion
and cell entry in all cell types is dictated by the core fusion machinery composed of gHgL and the
glycoprotein B (gB) which are thus considered as primary targets for vaccine development [2]. gB is
a class III viral fusion protein that forms homotrimers (Figure 1) and was initially reported to bind
cell–surface proteins such as PDGFRα and EGFR. However, it is more likely that gB functions as a viral
fusogen that is triggered when viral and host membranes are in close proximity [82]. In addition to
the HCMV membrane glycoproteins, other viral antigens have been considered as potential vaccine
targets. The phosphoprotein 65 (pp65) encoded by pUL83 and the immediate-early protein 1 (IE1)
encoded by pUL123, both eliciting a robust T cell response, have undergone evaluation as subunit
or vectored vaccines in human [83,84]. In conclusion, the aforementioned vaccine candidates failed
to confer an appropriate protection from infection, viral reinfection or reactivation. We believe that
the development of a protective vaccine should include antigens from the viral envelope to trigger
the humoral response (mainly pentamer and newly designed gB) and antigens from the tegument or
proteins that are specifically associated with latency (i.e., US28) to prompt the cellular response able to
control viral reactivation.
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4. Virus-Like Particles and Nanoparticles for Antigen Display
Virus-like particles (VLPs) and nanoparticles (NPs) are protein structures that resemble wild
type viruses but do not have a viral genome nor infectious ability, creating in principle safer vaccine
candidates. Both VLPs and NPs are composed of self-assembling proteins displaying the epitope of
interest at a high density on their surface. Antigen presentation as a repetitive array is known to drive
stronger humoral immune responses when compared to the single soluble antigen [85]. This effect
is thought to derive from some key properties of the VLPs/NPs presentation such as the increased
antigen density that creates avidity leading to a stronger B cell activation through antigen-driven
cross-linking of B cell receptors (BCRs) [86]. Moreover, VLPs/NPs are also supposed to enhance
antigen uptake by antigen presenting cells (APCs) which subsequently support the adaptive arms
of the immune system [87]. Finally, VLPs/NPs have also been proven, in some cases, to generate an
epitope-focusing effect in which antigenic sites promoting the generation of potent neutralizing mAbs
were preferentially targeted [88,89]. Over the last decades, several platforms for VLPs/NPs design
have been generated, including the usage of viral core proteins, covalent links of individual folded
proteins through site-specific ligations and de novo protein nanostructure formation via non-covalent
intramolecular and intermolecular interactions. VLPs/NPs are currently recognized as one of the most
promising and extensively studied molecular carriers for new vaccine development. Here we will
present the current VLP HCMV vaccines in development and provide some examples that can be
relevant for novel vaccine design.
4.1. Developed HCMV VLP Vaccine
Enveloped virus-like particles (eVLPs) are VLP structures wrapped with a lipid envelope obtained
by transfection of the Moloney murine leukemia virus (MLV) gag protein in human or hamster cell lines
(i.e., HEK or CHO cells). The MLV gag expression induces burgeoning of particles from membranes of
transfected cells. Variation Biotechnologies Incorporated (VBI) laboratories generated an eVLP vaccine
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expressing an HCMV gB full-length or a chimeric gB protein, where the extracellular domain (ECD)
of gB is membrane-anchored using the transmembrane and cytoplasmic domains of the vesicular
stomatitis virus (VSV) G protein [90]. The chimeric gB-VSV-G protein is thought to maintain gB in
a prefusion conformation. Both vaccines were used to immunize mice and induce a neutralizing
antibody response 10-fold higher compared to their soluble recombinant protein counterpart [90].
The vaccine was entered in phase I clinical studies enrolling HCMV-seronegative individuals for
evaluation of safety and immunogenicity in early 2016 [91]. An additional eVLP vaccine candidate,
targeting both the gB and pp65 antigens, has also been manufactured by VBI. However, we believe that
a combination of gB, pentamer, and pp65 or US28 would be more appealing. Finally, another eVLP
HCMV vaccine candidate was developed by Redvax GmbH, a Swiss biopharmaceutical company.
Unlike VBI, that used mammalian cells, they used the rePAX baculovirus co-expression technology
minimizing the purification issues due to the relative large size of VLPs for the efficient generation of a
VLP vaccine candidate containing HCMV pp65 and gB [92]. Redvax GmbH was later acquired by
Pfizer and the vaccine was able to elicit high-titer neutralizing antibodies and good T cell responses
after immunization. Nonetheless, no protection was demonstrated from viremia upon challenge.
4.2. Hepatitis B Core Antigen Nanoparticle
The core protein of the hepatitis B virus (HBc) self-assembles into highly immunogenic virus-like
structures with icosahedral symmetry. The hepatitis B core nanoparticle (HBc) is assembled from
dimers of 183 or 185 amino acids and occurs in two size classes with a T = 3 or T = 4 symmetry.
Depending on the symmetry, HBc is formed by 90 or 120 dimeric subunits with a respective diameter
of 24 or 31 nm [93]. The antigen of interest needs to be inserted between alpha helices 3 and 4 of the
major immune-dominant region (MIR) domain (amino acids 78–82) (Figure 2A) of the HBc protein.
This insertion allows the antigen to be exposed on spike structures at the surface of the assembled
nanoparticle. HBc protomers first dimerize and then multimerize (Figure 2B,C). Several developments
led to the success of this platform, such as splitting of the HBc protein between the α3 and α4 helices
or fusing two monomers together using a flexible glycine serine linker that allowed the introduction of
larger protein domains [94,95]. However, one limitation of this technology is the need for both the N-
and C-termini of the inserted antigen to fit with the geometry of the core acceptor site, a requirement
that is not always successfully met by natively folded proteins.
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In summary, the HBc is a powerful platform to generate nanoparticles and it is particularly useful
in the case of small antigens. Indeed, it is unlikely that complex envelope glycoproteins such as gB or
the gHgL complexes could be correctly displayed on HBc particles. Nevertheless, HBc could be very
efficient to generate strong T cell responses [96]. For example, the viral-encoded G protein-coupled
receptor US28 was recently shown to aid in the establishment and the maintenance of viral latency.
US28 modulates host–cell proteins to suppress viral processes associated with lytic replication and
thereby represent an important target promoting latent infection [97]. HBc particles displaying US28
peptides recognized by T cells could provide an important advancement to boost the existing immune
responses necessary to control reactivation of latently infected individuals [98].
4.3. Ferritin-Based Nanoparticle
Ferritin is an intracellular globular protein that stores iron and releases it in a controlled fashion [99].
The protein is expressed in many tissues, mainly as a cytosolic protein, but it can be also found at
low concentration in the serum where it functions as an iron carrier [100]. Ferritin is a four-helix
bundle protein consisting of two couples of anti-parallel α-helices connected by a long loop and a
short C-terminal α-helix (Figure 3A). The monomer can dimerize and further self-assemble to form
a nanocage of 24 protein subunits, which has an internal and external diameter of 8 and 12 nm,
respectively [101]. Ferritin nanoparticle (ferritin-NP) presents the advantage of being resistant to
thermal and chemical stress [102]. Moreover, antigen display is achieved through genetic fusion at the
N-terminus of each ferritin protomer. Ferritin-NP self-arranges as an octahedron composed of eight
trimeric units (Figure 3B), each with a 3-fold symmetry axis that allows the correct presentation of
trimeric antigens at the nanoparticle surface (Figure 3C).
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to present HIV-1 and influenza antigens on the same particle [103]. Furthermore, Kanekiyo and 
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showed that immunization with this mosaic RBD-NP elicited a broad antibody response covering all
the known H1N1 strains. Multiple displays on ferritin-NP have opened up new possibilities for novel
vaccines against different pathogens or against different antigens of a given pathogen.
In the case of HCMV, we can speculate that a mosaic ferritin-NP displaying both pentamer and gB
ECDs should generate a potent humoral immune reaction. The antibodies generated targeting the gHgL
and gB subunits will block infection of connective tissues and stroma (containing fibroblasts). On the
other hand, antibodies directed against the pUL subunits will block infection of epithelial tissues.
4.4. Qβ Nanoparticle
The bacteriophage Qβ is a member of the Leviviridae family, forming 30 nm icosahedral
nanoparticles of 180 copies from the 14 kDa coat protein [105]. The coat protein monomer (Figure 4A)
forms Qβ dimers (Figure 4B) that further assemble into pentamers and hexamers by disulfide and
hydrogen bond interactions to form a Qβ nanoparticle under physiological conditions (Figure 4C). This
nanoparticle is highly stable and is used to display ligands and proteins on its exterior surface [106,107].
Co-expression of Qβ proteins displaying different antigens of interest or engineered Qβ proteins
displaying functionalized groups for subsequent direct antigen conjugation can be easily produced
in bacterial cells. Of note, the genetic fusion occurs at the C-terminus of the protein, a property that
might impair the correct folding of some antigens of interest. Genes encoding the viral Qβ protein
have been also successfully expressed in yeast cells but the possibility to generate a Qβ nanoparticle
in prokaryotic hosts, maintaining therefore a low production cost, will be of great interest for the
generation of a personalized T cell vaccine targeting the proteins associated to latency. Regarding
mammalian cell expression, there is currently no evidence that the system is also compatible with it,
which is a prerequisite for the production of most of the HCMV glycoprotein antigens.
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designing novel self-assembling proteins with atomic-level accuracy offer the possibility to design
self-assembling proteins with customized structures, offering new opportunities for structure-based
vaccine design [108–110]. For instance, the HIV gp41 ectodomain trimer was displayed onto the
I3–01 particle [108,111]. The gp41 antigen exposed on NPs, stimulated mAb-expressing B cells more
effectively than the soluble trimers [111]. Two additional publications highlighted the potential of
this de novo self-assembling nanoparticle for antigen display. The I5350 nanoparticle (Figure 5) was
used to generate an enhanced vaccine against the respiratory syncytial virus (RSV). Self-assembling
protein nanoparticles displaying 20 copies of the stabilized version of the RSV fusion glycoprotein
trimer (DS-Cav1) induced a neutralizing antibody response ∼10-fold higher than soluble trimeric
DS-Cav1 [112]. In the second case, native-like HIV-1 envelope trimer antigens were displayed in a
multivalent fashion on the I5350 nanoparticle scaffold and immunization studies revealed a more
effective priming compared to the soluble SOSIP trimers [113]. SOSIP corresponds to a stabilized
trimer with mutations that cross-link the cleaved gp120 and gp41. In contrast, the natural HIV trimer
is comprised of three copies of a non-covalently linked gp120/gp41 heterodimer arising from cleavage
of the viral gp160 precursor protein. It can be speculated that de novo design-based nanoparticles will
have an increasing impact on next generation vaccines since they are customizable at will, supported by
a multitude of expression platforms and able to generate multivalent display as well as encapsulation
of small proteins or compounds [114,115].
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Ideally, I5350 particles should present on their surface the pentamer and gB to generate a humoral
response against the gH, gL, pULs, and gB molecules. Moreover, as I5350 nanoparticles are hollow,
the in vitro assembly step with I53–50B.4PT1 could be performed in the presence of T-cell stimulating
peptides (i.e., pp65, IE1 and US28) that would be encapsulated inside the particles. The resulting vaccine
candidates should in this way stimulate both arms of the immune system, offering a maximal protection.
4.6. SpyCatcher and SpyTag for Nanoparticle Formation
The SpyTag/SpyCatcher system (referred as Spy-System) is based on the internal isopeptide bond
of the CnaB2 domain of FbaB protein from Streptococcus pyogenes. An internal isopeptide bond forms
spontaneously in this domain between the reactive amine of lysine K31 and the side chain carboxyl
of aspartate D117. This reaction is catalyzed by the spatially adjacent glutamate E77. The resulting
isopeptide bond confers high stability to the CnaB2 domain. The CnaB2 domain is cleaved into two
subcomponents, the large and incomplete immunoglobulin-like domain, named SpyCatcher, composed
of 138 amino acids, and the short beta strand, named SpyTag, composed of 13 amino acids [116]. While
the SpyCatcher contains the reactive lysine (K31) and catalytic glutamate (E77), the SpyTag includes
the reactive aspartate (D117). The two components can still recognize each other with high affinity
and the isopeptide is formed within minutes. Despite the fact that this system is not able to generate
nanoparticles on its own, the two components of the Spy-System can be genetically fused to a number of
viral or designed self-assembling proteins leading to the generation of a stable nanoparticle displaying
a large variety of antigens. Moreover, the Spy-System offers a great flexibility since components can be
inserted at the N- or C-termini of the target proteins. Its simplicity is of particular interest to quickly
screen if a nanoparticle formulation will be of benefit for vaccine design, before generating genetic
fusion on the nanoparticle of interest. The first nanoparticle assembly with Spy-System was performed
by genetically fusing the SpyCatcher to the N-terminus of the viral coat protein (CP3) of the RNA
bacteriophage AP205 [117]. AP205 VLPs have been then further investigated as vaccine candidates
against a number of targets, including malaria and cancer [117–119].
5. Conclusions and Future Directions
We described a large variety of systems to generate both VLPs and NPs. Self-assembling
scaffolds have been used to present complex glycoprotein antigens and for vaccination studies against
influenza [104], HIV [113,120–123], Epstein–Barr virus [89], and RSV [112]. In all cases, antigen
immunogenicity was increased by multivalent presentation and in some cases, an epitope focusing
effect could be observed. The rise of computational design to generate novel self-assembling proteins
has now paved the way for new possibilities to display antigens without limitation in term of quantity
or oligomeric state of the antigen. HCMV is still the principal viral cause of congenital malformations.
About one quarter of infants infected by HCMV in utero will develop severe sequelae including
microcephaly, sensorineural hearing and vision loss, or cognitive delay [1,6]. The recent identification
of key HCMV antigenic targets for both humoral and cellular immune responses and the capacity to
display and encapsulate proteins or nucleic acids (RNAs) on VLPs/NPs is likely to generate improved
vaccine candidates able to redirect the immune response against specific targets.
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